Ascendis Pharma A/S Stock News

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, Fe

Ascendis Pharma A/S (ASND) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Timothy Lee - Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott

• Third Quarter financial results and business update conference call to be held on November 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected before mid-Novem

The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street

Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executiv

COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday,

The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am

COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice Presi